Sumitomo Chemical India Q2 FY27 Earnings Call: Fourth-Weakest Monsoon Hits Kharif Demand, Rs. 150 Crore Dahej Capex Reaffirmed (SUMICHEM)

Sumitomo Chemical India Ltd held its Q2 FY27 earnings call on October 26, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Stable Top Line, Margin Compression on Inventory Timing

• Q2 FY 2026-2027 revenue of Rs.907 crore, down 2% YoY — vs Rs.930 crore in Q2 FY 2025-2026; H1 FY 2026-2027 revenue was Rs.1,971 crore, down 1% YoY, broadly in line with H1 FY 2025-2026 despite a clear fall in industry volumes and demand.
• Q2 EBITDA of Rs.187 crore, down 15% YoY — EBITDA margin of 20.5% (down 297 bps YoY) and gross margin of 40.7% (down 240 bps YoY) hit as higher-cost inventory bought in April–June 2026 flowed into Q2 cost of sales; gross margin was up 149 bps sequentially vs Q1 FY 2026-2027, and inventory costs had largely normalized by end of Q2.
• Q2 net profit declined 11% to Rs.157 crore — net margin of 17.3% vs Rs.178 crore in Q2 FY 2025-2026; employee cost (Rs.70 crore) and other opex (Rs.113 crore) were largely flat YoY.
• H1 FY 2026-2027 net profit rose 5% to Rs.372 crore — net margin 18.9% (up 96 bps); H1 EPS Rs.7.45 vs Rs.7.13; PBT including exceptional items was Rs.498 crore, up 4%, with Q1 including Rs.20.9 crore exceptional insurance income for the FY23 Bhavnagar plant fire business interruption.
• Domestic revenue grew 2% YoY to Rs.774 crore in Q2 — H1 domestic broadly stable at Rs.1,657 crore; branded products made up ~79% of domestic revenue; Q2 sales volumes fell by a high single-digit% on lower consumption in adverse weather.
• Q2 exports fell 23% YoY to Rs.127 crore — mainly on timing of shipments to Japan and South America; H1 exports stable at ~Rs.300 crore, with Africa, South America, Asia and Europe each growing 15–19%.

Fourth-Weakest Monsoon Since 2001 Weighs on Kharif

• IMD data showed June rainfall ~35% below normal and a season deficit of ~13% — management cited "the fourth weakest monsoon since 2001 and weakest since 2015"; East/Northeast India had its lowest rainfall since 1901, and IMD declared India officially a drought year.
• Kharif FY 2026-2027 acreage ended ~1.5% below normal (rice down ~4%) — production of rice, cotton, soybean, groundnut, pulses and oilseeds estimated lower by almost 10% depending on crop; delayed sowing and dry spells cut herbicide consumption and farmers skipped spray rounds in August–September 2026.
• WMO expects El Niño to strengthen further, peak around December and continue through February 2027 — management noted it "could be one of the strongest El Niño events since 1950", overlapping the Rabi season; reservoirs at ~71% of capacity and at least 25% below year-ago levels.
• Key specialty brands grew despite the monsoon — Sumimax, Excalia Max, Portion, ProZip, Nature Dip, Tribasic Copper and Meshi together up ~22% in value in H1 FY 2026-2027 vs H1 FY 2025-2026.
• Offsetting tailwinds for H2 FY 2026-2027 — lower harvest estimates pushed up commodity prices (rice, cotton, pulses, oilseeds) supporting farmer incomes; wheat and cumin expected normal, grapes season looking better; rice area expected to decline in southern states on low water availability, and chilli depends on November–December rains in Andhra Pradesh and Karnataka.
• Government of India recently banned Paraquat — management said this will leave a vacuum for other molecules, and the glyphosate opportunity has the potential to increase as one of the molecules that can take that space; management will wait and watch how it unfolds.

Parent Inventory Liquidation Drives Export Setback

• Exports to Japan almost halved vs H1 FY 2025-2026 — Q2 FY 2026-2027 export weakness stemmed primarily from lower shipments to the parent company as it liquidates inventory built up over the last 2-3 years; management quantified the export volume impact at roughly 10% in FY 2026-2027.
• MD Suresh Ramachandran called the overstocking a FY 2026-2027 phenomenon — exports/Japan demand expected to return to normal in FY 2027-2028; direct third-party exports grew in H1 FY 2026-2027, led by Africa with limited gains in Brazil and Europe, while the US saw some impact.
• Branded share of export revenue rose to 41% in H1 FY 2026-2027 from 34% — management clarified this is real growth, not a mix effect, with Africa contributing a large part of the increase; specialty share fell to 28% from 30% while generics rose to 72% from 70% on higher price increases in line with the market.
• Analyst Vidrum Mehta (ASK Investment Managers) flagged flattish exports of Rs.680-700 crore annually over the last two years — ~Rs.300 crore in H1 FY 2026-2027 — and cited 10-15% rupee depreciation over the last 24 months (from Rs.82-83 to Rs.95/USD); management declined medium/long-term export growth guidance, citing a policy of not giving forward-looking estimates.
• Parent-company exports expected to remain on the softer side in H2 FY 2026-2027 — management is working to recover the high single-digit volume drop recorded in H1 FY 2026-2027; from FY 2027-2028, certain capex coming in could bring additional revenues in parent-company exports, framed as a possibility, not a commitment.

Dahej Greenfield, Tarapur Expansion and Specialty Launch Cadence

• Rs.150 crore Dahej herbicide intermediate capex reaffirmed — a dedicated facility for only one intermediate of one blockbuster herbicide; assumptions unchanged vs capex approval (January 2026): very healthy turnover ratios, payback of less than 5 years, and margin profile in line with company-level margins; commercialization expected in Q2 FY 2028-2029 (calendar 2028, roughly July-October), with management noting it may explore advancing by a few weeks.
• Dahej is a new greenfield site for development over the next 5 to 10 years — the parent company has just launched or is expected to launch 4 or 5 blockbuster products soon (period unspecified), each requiring multiple intermediates; additional projects are under evaluation, each requiring parent company and board approval.
• Two Tarapur capex projects of Rs.10 crore each (~Rs.20 crore total) will add 3–4 products — first part expected within FY 2026-2027, second by end of FY 2027-2028; Tarapur capex is targeted at expanding the domestic business, not exports; maintenance/debottlenecking capex historically runs at Rs.50-70 crore, with no forward capex guidance given.
• India elevated to top-tier in the parent's global launch hierarchy — alongside Brazil, Europe, US and Japan for first-tier testing and launch; management expects to introduce 1–2 new products every year over the next 3–5 years; specialty products take at least 4-5 years from discovery through testing and regulatory processes before commercialization.
• Indiflin (Excalia Max) India sales grew almost 50% in H1 FY 2026-2027 — launched in India in FY 2025-2026 and named a "blockbuster product"; Tarapur will manufacture Indian quantities by end of FY 2026-2027, with no firm export plans of Indiflin from India as of now and no approved capex for global requirement.
• Top Grain biostimulant launched ~7-8 weeks before the call — first global commercial launch — label claims secured on paddy and wheat; a full-fledged country-wide launch is planned for FY 2027-2028 with a wheat introduction in the February-March 2027 window (Q4 FY 2026-2027).
• Biorationals sized at ~4-5% of business globally and in India — while launched biorational products already generate almost 9-10% of India revenue (both FY 2026-2027); the parent's biorationals business is ~US$500 million currently (FY 2026-2027) and is expected to grow at a much faster pace than traditional chemistries (period unspecified); Barix potential unquantified — "very difficult to put a number as of now" after a rain-washout FY 2025-2026 and drought FY 2026-2027.

Parent MOU Signed; Listed Entity Role Undecided

• Parent Sumitomo Chemical Japan signed an MOU during SEMICON 2026 — with a leading Indian semiconductor player developing India's first semiconductor fabrication plant; discussions remain at MOU stage and are ongoing with all stakeholders, including the Indian government, for whom it is a very important project.
• First India fab expected operational in the next one or two years (≈FY 2027-2028 to FY 2028-2029) — per management's latest understanding; however, Sumitomo's products "are not the candidates to start immediately" as localization will take time.
• All client MOUs signed to date are with the parent entity — EVP Kunal Mittal confirmed Sumitomo Chemical India has not signed any MOU with any client as of now; the listed entity's role versus a wholly owned subsidiary of the parent will be finalized "in due course" once localization and investment plans reach a mature and firm level.
• Management declined to comment on probability of the arrangement landing in the listed entity — stating discussions have not yet matured enough for any formal announcement; a due announcement is expected in the next few months as the project gains more certainty and approvals.
• Analyst Abhishek Sharma (Nine Rivers Capital) argued the stock's premium rests on optionality — in pharma CDMO, electronic chemicals and semicon chemicals where the parent is already present; management acknowledged the views without committing, and noted strategic-level discussions with the parent on participating in its other India businesses have been ongoing (analyst: ~3 years) with no specific timelines given.

Cautious H2, Working Capital Elevated, "Good to Great" Launched

• H2 FY 2026-2027 margins expected in the normal historical range — EVP Kunal Mittal said no significant adverse factors in revenue or margin are projected "at this point of time"; Q2 margin dipped a few basis points as the Q1 low-cost inventory benefit partially reversed; no negative RM cost delta seen, and management concurs operating leverage should support profitability as revenue ramps up.
• No specific H2 revenue run-rate guidance — management emphasized maximizing opportunities across a "vast" market despite non-normal conditions; the H2 goal is to grow H2 FY 2026-2027 sales over H2 FY 2025-2026 levels where the market allows, while protecting profitability.
• Net working capital rose to 76 days from 55 days a year ago — driven by inventory days increasing to 115 from 95 on higher inventory costs plus softer Q2 offtake; corrective actions have begun and inventory is expected to normalize through H2 FY 2026-2027; sales returns are not expected to impact H2 FY 2026-2027 — any returns "very minuscule".
• Cash, cash equivalents and liquid investments of ~Rs.2,523 crore as of 30 September 2026 — up from Rs.2,113 crore in March 2026; H1 net cash from operations Rs.447 crore (vs Rs.435 crore); balance sheet essentially debt-free; management does not believe it should give up future growth to return cash to shareholders now, with the shareholder-return point to be put to the board.
• "Good to Great – Transform to Secure Our Future" program launched — five pillars (people, operational excellence, technology, data/digital/automation, cross-functional collaboration); efficiency levers include using AI for repetitive tasks and reducing own manufacturing costs; a quantified financial goal is to be finalized "in the next few weeks" (period unspecified).
• Growth acceleration from FY 2028 onwards is environment-dependent — newly launched products plus a couple more lined up over FY 2027-2028–FY 2028-2029 should support acceleration if the environment cooperates; management remains cautious on the near term but confident in the company's direction, citing a differentiated portfolio, deep farmer/channel relationships and a strong pipeline from parent Sumitomo Chemical.